Engineered virus effective against triple negative breast cancer cells, study shows

The discovery was published in the February 2014 issue of The FASEB Journal. Researchers stress that human clinical trials are necessary before any definitive claims of a cure can be made and treatments can be made available. “We hope that the recent advances in virology, genetic engineering and targeted radiotherapy will soon translate into an … Continue reading “Engineered virus effective against triple negative breast cancer cells, study shows”

The discovery was published in the February 2014 issue of The FASEB Journal.

Researchers stress that human clinical trials are necessary before any definitive claims of a cure can be made and treatments can be made available.

“We hope that the recent advances in virology, genetic engineering and targeted radiotherapy will soon translate into an entire class of novel oncolytic, virotherapies for the treatment of deadly cancers,” said Yuman Fong, M.D., a researcher involved in the work from the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York, NY.

To make this discovery, Fong and colleagues successfully infected and killed TNBC cells using a vaccinia virus. In addition, the researchers were also able to use the virus to cause infected cancer cells produce a cell surface protein called hNIS that normally is used to concentrate iodine in thyroid cells. The hNIS protein, expressed in thyroid cancer, is why most thyroid cancers can be cured or successfully treated with a small dose of radioactive iodine (which kills thyroid cancer cells expressing hNIS). Armed with the ability to force TNBC cells to produce this protein, researchers now have a way to deliver anticancer therapies to this deadly and resistant form of cancer.

“This is an important and significant discovery that basically combines proven cures for two other diseases,” said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. “Even more exciting is that the effects of this virus and radioactive iodine are well known in people, hopefully reducing the amount of time it will take for it to reach the clinic.”

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply